Bardoxolone Methyl (RTA 402)

Bardoxolone Methyl (RTA 402) is an activator of NRF2 and IKK used in studies of NF-kB Signaling and Immune Signaling and related signaling programs. It is especially relevant when investigators need a named chemical input and interpretable readouts connected to inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses in apoptosis, autophagy, and cancer models.

By activating NRF2 and IKK, Bardoxolone Methyl (RTA 402) can be used to examine inflammatory transcriptional control and stress-responsive survival signaling and cytokine-mediated signaling and inflammatory effector responses. The signaling pathway modulator annotation adds relevance to pathway-reporter and mechanistic-phenotyping studies, together with downstream-response mapping in the same experimental setting. In apoptosis, autophagy, and cancer models, these readouts can be combined with viability, reporter, localization, biochemical conversion, or morphology endpoints to refine experimental interpretation.

Research Applications

• Target-focused assays involving NRF2 and IKK
• Pathway perturbation studies connected to NF-kB Signaling and Immune Signaling and related signaling programs
• Gain-of-function pathway-activation studies
• Pathway-reporter and mechanistic-phenotyping studies

Overall, Bardoxolone Methyl (RTA 402) is appropriate when a defined chemical perturbant is needed to connect NRF2 and IKK with measurable biochemical, transcriptional, electrophysiological, imaging, or phenotypic readouts in apoptosis, autophagy, and cancer models. This profile is suited to mechanistic follow-up, comparative profiling, and assay optimization under defined exposure conditions.